John Muscedere1, Tasnim Sinuff2, Daren K Heyland3, Peter M Dodek4, Sean P Keenan5, Gordon Wood6, Xuran Jiang3, Andrew G Day3, Denny Laporta7, Michael Klompas8. 1. Department of Medicine, Kingston General Hospital, Queen's University, Kingston, ON. Electronic address: muscedej@kgh.kari.net. 2. Sunnybrook Research Institute, Sunnybrook Health Sciences Center and the Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, ON. 3. Department of Medicine, Kingston General Hospital, Queen's University, Kingston, ON. 4. Center for Health Evaluation and Outcome Sciences and Department of Medicine, Providence Health Care and University of British Columbia, Vancouver, BC. 5. Department of Critical Care Medicine, Fraser Health Authority, BC; Department of Medicine, University of British Columbia, Vancouver, BC. 6. Vancouver Island Health Authority, Victoria, BC. 7. Jewish General Hospital, McGill University, Montreal, QC, Canada. 8. Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA.
Abstract
BACKGROUND:Ventilator-associated conditions (VACs) and infection-related ventilator-associated complications (iVACs) are the Centers for Disease Control and Prevention's new surveillance paradigms for patients who are mechanically ventilated. Little is known regarding the clinical impact and preventability of VACs and iVACs and their relationship to ventilator-associated pneumonia (VAP). We evaluated these using data from a large, multicenter, quality-improvement initiative. METHODS: We retrospectively applied definitions for VAC and iVAC to data from a prospective time series study in which VAP clinical practice guidelines were implemented in 11 North American ICUs. Each ICU enrolled 30 consecutive patients mechanically ventilated > 48 h during each of four study periods. Data on clinical outcomes and concordance with prevention recommendations were collected. VAC, iVAC, and VAP rates over time, the agreement (κ statistic) between definitions, associated morbidity/mortality, and independent risk factors for each were determined. RESULTS: Of 1,320 patients, 139 (10.5%) developed a VAC, 65 (4.9%) developed an iVAC, and 148 (11.2%) developed VAP. The agreement between VAP and VAC was 0.18, and between VAP and iVAC it was 0.19. Patients who developed a VAC or iVAC had significantly more ventilator days, hospital days, and antibiotic days and higher hospital mortality than patients who had neither of these conditions. Increased concordance with VAP prevention guidelines during the study was associated with decreased VAP and VAC rates but no change in iVAC rates. CONCLUSIONS: VACs and iVACs are associated with significant morbidity and mortality. Although the agreement between VAC, iVAC, and VAP is poor, a higher adoption of measures to prevent VAP was associated with lower VAP and VAC rates.
RCT Entities:
BACKGROUND: Ventilator-associated conditions (VACs) and infection-related ventilator-associated complications (iVACs) are the Centers for Disease Control and Prevention's new surveillance paradigms for patients who are mechanically ventilated. Little is known regarding the clinical impact and preventability of VACs and iVACs and their relationship to ventilator-associated pneumonia (VAP). We evaluated these using data from a large, multicenter, quality-improvement initiative. METHODS: We retrospectively applied definitions for VAC and iVAC to data from a prospective time series study in which VAP clinical practice guidelines were implemented in 11 North American ICUs. Each ICU enrolled 30 consecutive patients mechanically ventilated > 48 h during each of four study periods. Data on clinical outcomes and concordance with prevention recommendations were collected. VAC, iVAC, and VAP rates over time, the agreement (κ statistic) between definitions, associated morbidity/mortality, and independent risk factors for each were determined. RESULTS: Of 1,320 patients, 139 (10.5%) developed a VAC, 65 (4.9%) developed an iVAC, and 148 (11.2%) developed VAP. The agreement between VAP and VAC was 0.18, and between VAP and iVAC it was 0.19. Patients who developed a VAC or iVAC had significantly more ventilator days, hospital days, and antibiotic days and higher hospital mortality than patients who had neither of these conditions. Increased concordance with VAP prevention guidelines during the study was associated with decreased VAP and VAC rates but no change in iVAC rates. CONCLUSIONS: VACs and iVACs are associated with significant morbidity and mortality. Although the agreement between VAC, iVAC, and VAP is poor, a higher adoption of measures to prevent VAP was associated with lower VAP and VAC rates.
Authors: Nishi Rawat; Ting Yang; Kisha J Ali; Mary Catanzaro; Mariah D Cohen; Donna O Farley; Lisa H Lubomski; David A Thompson; Bradford D Winters; Sara E Cosgrove; Michael Klompas; Kathleen A Speck; Sean M Berenholtz Journal: Crit Care Med Date: 2017-07 Impact factor: 7.598
Authors: John C O'Horo; Rahul Kashyap; Ronaldo Sevilla Berrios; Vitaly Herasevich; Priya Sampathkumar Journal: Am J Infect Control Date: 2016-02-18 Impact factor: 2.918
Authors: Meghan M Cirulis; Mitchell T Hamele; Chris R Stockmann; Tellen D Bennett; Susan L Bratton Journal: Pediatr Crit Care Med Date: 2016-02 Impact factor: 3.624